177Lu-DOTA-LM3用于转移性神经内分泌肿瘤的首次人体研究:剂量学、安全性与疗效
该研究评估了177Lu标记的SSTR拮抗剂177Lu-DOTA-LM3在51例转移性神经内分泌肿瘤患者中的安全性、剂量学和疗效,并与177Lu-DOTATOC激动剂进行剂量学比较。结果显示该拮抗剂耐受良好,无严重急性不良反应,疾病控制率达85.1%,且较激动剂具有更高的肿瘤吸收剂量。
要点
- 177Lu-DOTA-LM3耐受良好,仅5.9%患者出现CTC-3血小板减少,无肾毒性。
- RECIST 1.1评估疾病控制率85.1%,部分缓解36.2%,稳定48.9%。
- 较177Lu-DOTATOC激动剂,177Lu-DOTA-LM3在全身、肾、脾和转移灶中摄取更高、有效半衰期更长,吸收剂量更高。
核心结论
- 177Lu-DOTA-LM3拮抗剂PRRT无严重不良反应,耐受良好,仅少数患者出现血小板减少,无肾毒性。
- 该拮抗剂生物分布良好,肿瘤辐射剂量高于SSTR激动剂,对晚期转移性NEN有效,尤其在SSTR激动剂结合低或无的患者中,部分可达完全缓解。
研究设计与样本
- 研究纳入51例转移性神经内分泌肿瘤患者(年龄27-76岁,平均51.6±13.9岁),于2017年8月至2019年12月接受177Lu-DOTA-LM3 PRRT。
- 每周期中位给药活度为6.1±0.88 GBq(范围2.8-7.4 GBq),用68Ga-NODAGA-LM3 PET/CT进行患者筛选和随访。
- 剂量学在11例患者中进行,并与247例接受同一剂量学方案PRRT的177Lu-DOTATOC患者比较。
主要发现
- 177Lu-DOTA-LM3在全身、肾脏、脾脏和转移灶中的摄取和有效半衰期高于177Lu-DOTATOC,导致更高的平均吸收器官和肿瘤剂量。
- 所有患者耐受治疗,无严重急性不良反应;5例(9.8%)出现轻度恶心无呕吐,未报告其他症状。
- 最严重的延迟不良事件为CTC-3血小板减少3例(5.9%),未观察到CTC-4血小板减少或CTC-3-4贫血或白细胞减少,无显著肾功能下降或肝毒性。
- 按RECIST 1.1评估47例可监测患者,疾病控制40例(85.1%),部分缓解17例(36.2%),稳定23例(48.9%),进展7例(14.9%)。
- 按EORTC标准,完全缓解2例(4.3%),部分缓解21例(44.7%),稳定18例(38.3%),进展6例(12.8%)。
关键数值与推荐
- 形态学反应依据RECIST 1.1评估,分子反应依据EORTC标准评估。
- 不良事件依据NCI CTCAE 5.0版分级。
- RECIST 1.1疾病控制率85.1%(40/47),部分缓解36.2%(17/47),稳定48.9%(23/47),进展14.9%(7/47)。
- EORTC标准完全缓解4.3%(2/47),部分缓解44.7%(21/47),稳定38.3%(18/47),进展12.8%(6/47)。
临床怎么用
- 177Lu-DOTA-LM3可用于转移性NEN的PRRT,耐受性好,尤其适用于SSTR激动剂结合低或无的患者。
- 治疗前用68Ga-NODAGA-LM3 PET/CT筛选患者并随访,治疗中监测血小板和肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2 (177Lu-DOTA-LM3) in patients with metastatic neuroendocrine neoplasms (NENs). Methods: Fifty-one patients (aged 27-76 y; mean, 51.6 ± 13.9 y) with metastatic NENs underwent peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-LM3 between August 2017 and December 2019. The median administered activity per cycle was 6.1 ± 0.88 GBq (range, 2.8-7.4 GBq). 68Ga-NODAGA-LM3 PET/CT was used for patient selection and follow-up after 177Lu-DOTA-LM3 PRRT. Morphologic and molecular responses were evaluated in accordance with RECIST 1.1 and the criteria of the European Organisation for Research and Treatment of Cancer (EORTC). Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Dosimetry was performed on 11 patients and compared with the SSTR agonist 177Lu-DOTATOC in 247 patients undergoing PRRT on the same dosimetry protocol. Results: Higher uptake and a longer effective half-life were found for 177Lu-DOTA-LM3 than for the agonist 177Lu-DOTATOC in the whole body and in the kidneys, spleen, and metastases, resulting in higher mean absorbed organ and tumor doses. All patients tolerated therapy without any serious acute adverse effects. Mild nausea without vomiting was observed in 5 (9.8%) patients; no other symptoms were reported. The most severe delayed adverse event was Common Terminology Criteria (CTC)-3 thrombocytopenia in 3 (5.9%) patients. Neither CTC-4 thrombocytopenia nor CTC-3-4 anemia or leukopenia was observed after treatment. No significant decline in renal function was observed, nor was hepatotoxicity. According to RECIST 1.1, disease control could be reached in 40 patients (disease control rate, 85.1%) of the 47 patients monitored after 177Lu-DOTA-LM3 PRRT, with a partial response in 17 (36.2%) and stable disease in 23 (48.9%), whereas 7 patients (14.9%) had progressive disease, and by EORTC criteria, there was complete remission in 2 patients (4.3%), partial remission in 21 (44.7%), stable disease in 18 (38.3%), and progressive disease in 6 (12.8%). Conclusion: The antagonist PRRT with 177Lu-DOTA-LM3 could be administered without severe adverse effects and was well tolerated by most patients, with thrombocytopenia occurring in only a few. No other severe adverse effects were observed; in particular, there was no nephrotoxicity. The SSTR antagonist 177Lu-DOTA-LM3 appears to be promising for PRRT, provides a favorable biodistribution and higher tumor radiation doses than SSTR agonists, and was effective in treating advanced metastatic NENs, especially in patients with low or no SSTR agonist binding, even achieving complete remission in some patients.
引用
- Baum RP, Zhang J, Schuchardt C, et al. First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021. PMID: 33674401. doi:10.2967/jnumed.120.258889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。